Since these data may support testing new generation of anti-CTLA-4 antibodies in clinical trials, we decided to perform an in-depth analysis of tumor-infiltrating T cells in human to predict selectivity of anti-CTLA-4 antibody-induced Treg depletion. The gene discussed is CTLA4; the disease is neoplasm.